Acrivon Therapeutics, Inc. (ACRV)
(Delayed Data from NSDQ)
$7.95 USD
-0.16 (-1.97%)
Updated May 24, 2024 04:00 PM ET
After-Market: $7.92 -0.03 (-0.38%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACRV 7.95 -0.16(-1.97%)
Will ACRV be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ACRV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACRV
5 Small Drug Stocks to Buy From a Recovering Industry
Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?
ACRV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season?
Catalyst (CPRX) to Report Q1 Earnings: What's in the Cards?
Other News for ACRV
Acrivon Therapeutics: A Buy Rating on Strong Clinical and Financial Prospects
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics price target raised by $2 at H.C. Wainwright, here's why
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), Arcutis Biotherapeutics (ARQT) and TruBridge (TBRG)